Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Electroporation is a useful molecular biology technique that allows for non-chemical transformation of bacteria and yeasts as well as transfection of tissue culture cells (e.g. mammalian cells). Electroporation systems deliver short bursts of a high-intensity electric field to cells. The electrical field makes the cell membrane more permeable. As a result, chemicals such as drugs and genetic material can pass through the cell membrane, which would otherwise be impermeable. Due to its ease of use and efficacy, electroporation is a popular method for introducing foreign genes into target cells.
In addition to direct gene introduction, electroporation allows for the direct transfer of plasmids between cells or species—for instance, from bacteria to yeast. Extensive research is ongoing on the use of electroporation to deliver medicines and vaccines directly to the cells of living organisms.
Electroporation systems are commonly used for the treatment of cancer through vaccine delivery, gene delivery or drug delivery that is electro-chemotherapy, for instance bleomycin. Vaccine delivery can also be used for treatment of infectious disease such as Human immunodeficiency virus (HIV).
Global Electroporation Instruments Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 195 million cases and 4.19 million deaths due to coronavirus disease (COVID-19) were reported till July 29, 2021, across the globe.
Impact of COVID-19 on Demand and Supply of Electroporation Instruments
The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
However, the COVID-19 pandemic might have a positive impact and boost the growth of the global electroporation instruments market over forecast period, owing to the use of electroporation in delivering of vaccines and drugs for the treatment of COVID-19. For instance, according to news article published in Eureka, blog of Charles River Laboratories Inc., U.S. on January 13, 2021, as the race for a COVID-19 vaccine intensified, researchers began looking for better, more effective drug delivery systems. Electroporation is one such in vivo drug delivery technology (EP). It has been demonstrated that electroporation has a significant impact on vaccine immunogenicity and efficacy. This is due to the fact that it has the potential to increase antigen delivery by up to 1000-fold when compared to naked DNA delivery technologies alone. The increase in antigen delivery results in a greater magnitude of immune response as well as higher response rates when compared to DNA delivery via direct injection alone.
The global electroporation instruments market is estimated to be valued at US$ 769.0 Mn in 2021, and is expected to exhibit a CAGR of 4.4 % over the forecast period (2021-2028).
Figure 1: Global Electroporation Instruments Market Share (%) Analysis, By Product Type (Instruments), 2021
As electroporation is used to treat various cancers, the prevalence of cancer is the major factor that is expected to drive the growth of global electroporation instruments market over the forecast period.
The emerging prevalence of cancers is expected to bolster the growth of global electroporation instruments market as electroporation helps in the treatment of cancers. For instance, according to the World Health Organization report 2020, cancer is the leading cause of death in the world, accounting for nearly ten million deaths in 2020. In terms of new cancer cases worldwide, the most common were: 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.4 million cases of prostate, 1.20 million cases of skin, 1.93 million cases of coon & rectum, and 1.09 million cases of stomach.
Electroporation Instruments Market Report Coverage
||Market Size in 2021:
||US$ 769.0 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 1,036.6 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Product Type: Instruments (Total Electroporation System, Transfection System, Microbial Electroporation System), Accessories (Electroporated Cuvettes, Electrodes, Volume Chambers, Others)
- By Application: Protein Production, Therapeutic Delivery, Biomedical Research
- By End User: Hospital Laboratories, Research & Academic Institutes, Biotechnology or Pharmaceutical Industries
Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Harvard Bioscience Inc. (BTX), Celetrix LLC, Mirus Bio LLC, Merck KGaA, Eppendorf AG, MaxCyte Inc., BEX Co. Ltd., and Lonza Group
- Increasing cases of cancer
- Increasing partnerships and agreements within market players
- Increasing product launches and approvals
Agreements, Partnerships, and Acquisition
Market players are adopting strategies such as agreements, partnerships or acquisitions which is expected to aid in the growth of the global electroporation instruments market over the forecast period. For instance, on June 16, 2020, Immunomic Therapeutics Inc., a privately held clinical-stage biotechnology company, entered into a license agreement with Ichor Medical Systems, a privately held biotechnology company based in California, U.S., to use Electroporation (EP) Delivery Technology in the Phase I study of ITI-1001, a DNA vaccine therapy. When administered to patients with newly diagnosed Glioblastoma, or GBM, Ichor's TriGrid Electroporation technology will help in increasing the cellular uptake of ITI-1001 which is in development by Immunomic Therapeutics.
Global Electroporation Instruments Market – Regional Analysis
On the basis of region, the global electroporation instruments market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among regions, North America is expected to hold dominant position in the global electroporation instruments market over the forecast period, owing to the launches and approvals of electroporation systems. For instance, on October 15, 2020, Precigen Inc., a biopharmaceutical company, announced the U.S. Food and Drugs Administration (FDA) clearance and successful technology transfer for its UltraPorator system, a high-throughput, semi-closed electroporation system for reprograming T-cells that uses Precigen's Sleeping Beauty non-viral gene transfer technology. In accordance with current good manufacturing practices (cGMP), the U.S. FDA approved UltraPorator as a manufacturing device for clinical trials of Precigen's investigational UltraCAR-T therapies.
Moreover, Europe is expected to witness a significant growth in global electroporation instruments market over the forecast period, owing to the launches and approvals of electroporation systems. For instance, on April 14, 2021, OncoSec Medical Inc., a biotechnology company focused on cytokine-based intratumoral immunotherapies, announced that it has been granted CE (European conformity) marking for its proprietary next generation go-to-market gene delivery device, GenPulse, which is part of the OncoSec Medical System (OMS) electroporation device platform for use in solid tumors. CE marking denotes that a product has been evaluated by the manufacturer and found to meet European Union (EU) safety, health, and environmental protection standards.
Figure 2: Global Electroporation Instruments Market Value (US$ Mn), By Region, 2021
Global Electroporation Instruments Market – Competitive Landscape
Major players operating in the global electroporation instruments market include Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Harvard Bioscience Inc. (BTX), Celetrix LLC, Mirus Bio LLC, Merck KGaA, Eppendorf AG, MaxCyte Inc., BEX Co. Ltd., and Lonza Group.